Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GLA | P06280 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.37 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27842484 | 0.81 | CYP1A2 (0.41) | CYP1A2ALDH1A1GLAHPGDMAPT | |
| SCHEMBL17061539 | 0.78 | CYP1A2 (0.47) | CYP1A2ALDH1A1GLAHPGDMAPT | |
| Hydrochloric Acid SCHEMBL27823349 | 0.77 | CYP1A2 (0.41) | CYP1A2ALDH1A1GLAHPGDMAPT | |
| Hydrochloric Acid SCHEMBL10583130 | 0.77 | CYP1A2 (0.47) | CYP1A2KDM4EEGFRNPC1RAB9A | |
| SCHEMBL4487839 | 0.76 | ALDH1A1 (0.43) | CYP1A2ALDH1A1GLAHPGDMAPT | |
| SCHEMBL12003727 | 0.75 | CYP1A2 (0.56) | CYP1A2ALDH1A1GLAHPGDMAPT | |
| SCHEMBL31391395 | 0.75 | CYP1A2 (0.56) | CYP1A2ALDH1A1GLAHPGDMAPT | |
| SCHEMBL2267486 | 0.75 | CFTR (0.40) | CYP1A2ALDH1A1KDM4EGPR3EGFR | |
| SCHEMBL7511419 | 0.74 | ALDH1A1 (0.41) | CYP1A2ALDH1A1MAPTKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL10583489 | 0.73 | MAPT (0.48) | CYP1A2ALDH1A1HPGDMAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4739306-A2 | POLO-LIKE KINASE 1 INHIBITORS | Cervero Therapeutics, LLC (US) | 2026-05-13 | — | — | EP | disclosed |
| CN-109305944-B | Inhibitors of bruton's tyrosine kinase | 深圳睿熙生物科技有限公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20220017484-A1 | INHIBITOR OF BRUTON TYROSINE KINASE | BEIJING RECIPROCAPHARMACEUTICALS CO., LTD. (CN) | 2022-01-20 | — | — | US | disclosed |
| EP-3882241-A1 | INHIBITOR OF BRUTON'S TYROSINE KINASE | Beijing Reciprocapharmaceuticals Co., Ltd. (CN) | 2021-09-22 | — | — | EP | disclosed |
| CN-111170986-A | Inhibitors of bruton's tyrosine kinase | 北京睿熙生物科技有限公司 | 2020-05-19 | — | — | CN | disclosed |
| CN-109305944-A | The inhibitor of bruton's tyrosine kinase | 深圳睿熙生物科技有限公司 | 2019-02-05 | — | — | CN | disclosed |
| US-7572798-B2 | Prevent Dna damage; antitumor, anticancer agents; blocking epidermal growth factor receptor | MCGILL UNIVERSITY (CA) | 2009-08-11 | — | — | US | disclosed |
| EP-1366027-B1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | UNIV MCGILL (CA) | 2006-09-20 | — | — | EP | disclosed |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | QIU, QIYU | 2004-05-06 | — | — | US | disclosed |
| EP-1366027-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | McGILL UNIVERSITY (CA) | 2003-12-03 | — | — | EP | disclosed |
| WO-2002068396-A1 | COMBI-MOLECULES HAVING SIGNAL TRANSDUCTION INHIBITORY PROPERTIES AND DNA DAMAGING PROPERTIES | MCGILL UNIVERSITY (CA) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017484-A1 | INHIBITOR OF BRUTON TYROSINE KINASE | BTK, LYN, SYK | CYP1A2 1994/4885ALDH1A1 3933/4885GLA 2879/4885 |
| US-20040086907-A1 | Combi-molecules having signal transduction inhibitory properties and dna damaging properties | EGFR, PCNA, ERCC2 | CYP1A2 4622/4885ALDH1A1 2925/4885GLA 1695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.